MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Veru Net Income 2011-2026 | VERU
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.8 M | -93.2 M | -38.7 M | 7.39 M | -19 M | -12 M | -23.9 M | -6.61 M | 345 K | 4.35 M | 2.43 M | 14.3 M | 15.3 M | 5.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.3 M | -93.2 M | -13 M |
Quarterly Net Income Veru
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.33 M | - | -7.33 M | -7.9 M | -8.95 M | - | -11 M | -10 M | -8.28 M | - | -12.5 M | -33.8 M | -38.7 M | -42.8 M | -22.2 M | -14.2 M | -6.38 M | 11.7 M | -2.69 M | -2.85 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | -3.31 M | -3.31 M | -3.31 M | -3.31 M | -2.15 M | -2.15 M | -2.15 M | -2.15 M | -4.26 M | -2.68 M | -790 K | -4.26 M | -1.37 M | -1.75 M | 570 K | -1.37 M | 1.49 M | 703 K | 1.17 M | 1.49 M | 805 K | -566 K | 1.16 M | 805 K | 1.46 M | 6.59 M | 727 K | 1.46 M | 3.53 M | 7.11 M | 2.55 M | 3.53 M | 2.66 M | 884 K | 417 K | 2.66 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.2 M | -42.8 M | -2.65 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Assertio Holdings
ASRT
|
-30.4 M | $ 18.41 | -1.02 % | $ 118 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | USA |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 3.14 | 2.28 % | $ 44.1 M | USA |
 |
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 2.53 | 0.4 % | $ 1.33 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-592 M | $ 5.35 | 1.71 % | $ 1.95 B | Canada |
 |
Aurora Cannabis
ACB
|
-695 M | $ 3.43 | 1.78 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.04 | 4.83 % | $ 112 M | Canada |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
Harrow Health
HROW
|
-5.14 M | $ 36.73 | 3.67 % | $ 1.35 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
-51.6 M | $ 4.09 | 0.25 % | $ 264 M | USA |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 8.39 | 6.88 % | $ 430 M | USA |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.39 | 1.46 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 2.39 | 5.75 % | $ 315 M | USA |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 23.25 | 3.2 % | $ 1.08 B | USA |
 |
Relmada Therapeutics
RLMD
|
-57.4 M | $ 7.01 | 3.85 % | $ 277 M | USA |
 |
SCYNEXIS
SCYX
|
-8.61 M | $ 1.0 | 3.87 % | $ 49.9 M | USA |
 |
Solid Biosciences
SLDB
|
-174 M | $ 8.02 | 3.62 % | $ 702 M | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-230 M | $ 1.36 | 3.82 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 2.29 | 3.62 % | $ 2.84 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 6.75 | 4.49 % | $ 4.17 B | Canada |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
54.7 M | $ 13.57 | 3.12 % | $ 16.3 B | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-153 K | $ 0.7 | -0.19 % | $ 3.02 M | USA |
 |
Zomedica Corp.
ZOM
|
-81.9 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-5.31 M | $ 0.94 | -1.12 % | $ 33.8 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.62 | 1.57 % | $ 2.66 M |  China |
 |
TherapeuticsMD
TXMD
|
-569 K | $ 2.05 | 1.49 % | $ 23.7 M | USA |